Back to Search
Start Over
Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
- Source :
- American Journal of Clinical Nutrition; Jan2016, Vol. 103 Issue 1, p66-70, 5p
- Publication Year :
- 2016
-
Abstract
- Background: Resveratrol has been reported to lower glycemia in rodent models of type 2 diabetes associated with the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow gastric emptying, stimulate insulin secretion, and suppress glucagon secretion and energy intake. Objective: We evaluated the effects of 5 wk of resveratrol treatment on GLP-1 secretion, gastric emptying, and glycemic control in type 2 diabetes. Design: Fourteen patients with diet-controlled type-2 diabetes [mean ± SEM glycated hemoglobin (HbA1c): 6.4 ± 0.2% (46.4 ± 2.2 mmol/mol)] received resveratrol (500 mg twice daily) or a placebo over two 5-wk intervention periods with a 5-wk washout period in between in a double-blind, randomized, crossover design. Before and after each intervention period (4 visits), body weight and HbA1c were measured, and patients were evaluated after an overnight fast with a standardized mashed-potato meal labeled with 100 µg <superscript>13</superscript>C-octanoic acid to measure blood glucose and plasma GLP-1 concentrations and gastric emptying (breath test) over 240 min. Daily energy intake was estimated from 3-d food diaries during the week before each visit. Results: Fasting and postprandial blood glucose and plasma total GLP-1 as well as gastric emptying were similar at each assessment, and the change in each variable from weeks 0 to 5 did not differ between resveratrol and placebo groups. Similarly, changes in HbA1c, daily energy intake, and body weight after 5 wk did not differ between the 2 treatments. Conclusions: In patients with diet-controlled type 2 diabetes, 5 wk of twice-daily 500 mg-resveratrol supplementation had no effect on GLP-1 secretion, glycemic control, gastric emptying, body weight, or energy intake. Our observations do not support the use of resveratrol for improving glycemic control. This trial was registered at www.anzctr.org.au as ACTRN12613000717752. [ABSTRACT FROM AUTHOR]
- Subjects :
- BLOOD sugar analysis
BODY weight
BREATH tests
CROSSOVER trials
DIETARY supplements
GASTROINTESTINAL motility
GLYCOSYLATED hemoglobin
INGESTION
TYPE 2 diabetes
NUTRITIONAL assessment
PROBABILITY theory
RESEARCH funding
STATISTICAL sampling
T-test (Statistics)
GLUCAGON-like peptide 1
STATISTICAL power analysis
RESVERATROL
BODY mass index
RANDOMIZED controlled trials
PRE-tests & post-tests
BLIND experiment
FOOD diaries
DATA analysis software
DESCRIPTIVE statistics
GLYCEMIC control
Subjects
Details
- Language :
- English
- ISSN :
- 00029165
- Volume :
- 103
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- American Journal of Clinical Nutrition
- Publication Type :
- Academic Journal
- Accession number :
- 112136761
- Full Text :
- https://doi.org/10.3945/ajcn.115.117440